191 related articles for article (PubMed ID: 32771660)
1. Cytotoxicity in Epstein Barr virus specific immune control.
Münz C
Curr Opin Virol; 2021 Feb; 46():1-8. PubMed ID: 32771660
[TBL] [Abstract][Full Text] [Related]
2. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
3. Epstein Barr virus - a tumor virus that needs cytotoxic lymphocytes to persist asymptomatically.
Münz C
Curr Opin Virol; 2016 Oct; 20():34-39. PubMed ID: 27591678
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Chatterjee B; Deng Y; Holler A; Nunez N; Azzi T; Vanoaica LD; Müller A; Zdimerova H; Antsiferova O; Zbinden A; Capaul R; Dreyer JH; Nadal D; Becher B; Robinson MD; Stauss H; Münz C
PLoS Pathog; 2019 May; 15(5):e1007748. PubMed ID: 31145756
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
6. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
8. EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.
Yuling H; Ruijing X; Li L; Xiang J; Rui Z; Yujuan W; Lijun Z; Chunxian D; Xinti T; Wei X; Lang C; Yanping J; Tao X; Mengjun W; Jie X; Youxin J; Jinquan T
Cancer Res; 2009 Oct; 69(20):7935-44. PubMed ID: 19808969
[TBL] [Abstract][Full Text] [Related]
9. [Anything that can go wrong: cytotoxic cells and their control of Epstein-Barr virus].
Gutiérrez-Guerrero A; Espinosa-Padilla SE; Lugo-Reyes SO
Rev Alerg Mex; 2024 Feb; 71(1):29-39. PubMed ID: 38683066
[TBL] [Abstract][Full Text] [Related]
10. Innate immune responses against Epstein Barr virus infection.
Chijioke O; Azzi T; Nadal D; Münz C
J Leukoc Biol; 2013 Dec; 94(6):1185-90. PubMed ID: 23812328
[TBL] [Abstract][Full Text] [Related]
11. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
12. Probing Reconstituted Human Immune Systems in Mice With Oncogenic γ-Herpesvirus Infections.
Münz C
Front Immunol; 2020; 11():581419. PubMed ID: 33013936
[TBL] [Abstract][Full Text] [Related]
13. The immunology of Epstein-Barr virus-induced disease.
Taylor GS; Long HM; Brooks JM; Rickinson AB; Hislop AD
Annu Rev Immunol; 2015; 33():787-821. PubMed ID: 25706097
[TBL] [Abstract][Full Text] [Related]
14. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
Latour S; Winter S
Front Immunol; 2018; 9():1103. PubMed ID: 29942301
[TBL] [Abstract][Full Text] [Related]
15. Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo.
Poon K; Montamat-Sicotte D; Cumberbatch N; McMichael AJ; Callan MF
Viral Immunol; 2005; 18(3):513-22. PubMed ID: 16212530
[TBL] [Abstract][Full Text] [Related]
16. Modification of EBV Associated Lymphomagenesis and Its Immune Control by Co-Infections and Genetics in Humanized Mice.
Schuhmachers P; Münz C
Front Immunol; 2021; 12():640918. PubMed ID: 33833760
[TBL] [Abstract][Full Text] [Related]
17. EBV Infection of Mice with Reconstituted Human Immune System Components.
Münz C
Curr Top Microbiol Immunol; 2015; 391():407-23. PubMed ID: 26428383
[TBL] [Abstract][Full Text] [Related]
18. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
[TBL] [Abstract][Full Text] [Related]
19. Humanized mouse models for Epstein Barr virus infection.
Münz C
Curr Opin Virol; 2017 Aug; 25():113-118. PubMed ID: 28837889
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
